In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001  by Jones, M.E. et al.
ORIGINAL ARTICLE
In vitro susceptibility of Streptococcus pneumoniae, Haemophilus
influenzae and Moraxella catarrhalis: a European multicenter study
during 2000–2001
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Objective To assess the current (2001) activity of respiratory fluoroquinolones and
comparator agents against respiratory pathogens isolated in European countries.
Methods During 2000–2001, we prospectively collected 1995 isolates of Haemophilus
influenzae, 1870 isolates of Streptococcus pneumoniae and 649 isolates of Moraxella catarrhalis
from hospital laboratories in France, Germany, Greece, Italy, Spain and the UK. National
Committee for Clinical Laboratory Standards (NCCLS)-approved broth microdilu-
tion antimicrobial susceptibility testing methods and interpretive criteria were used
throughout.
Results Of the S. pneumoniae isolates, 99.6% were susceptible to moxifloxacin, gatifloxacin
and levofloxacin; the corresponding figure for H. influenzae was 100%. All M. catarrhalis
isolates had moxifloxacin MICs 0.12 mg/L. For all three pathogens, fluoroquinolone
susceptibility remained unchanged from the previous 1997–98 study. The incidence of
penicillin non-susceptibility in the S. pneumoniae isolates tested remained similar to or
higher than that recorded in previous studies: France, 165/291 (56.7%); Germany, 46/506
(9.1%); Greece, 20/55 (36.4%); Italy, 45/364 (12.4%); Spain, 146/268 (54.5%); and the UK,
26/386 (6.7%). Significant levels of resistance to oral compounds (cefuroxime, cefaclor,
cefdinir, clarithromycin, azithromycin, tetracycline, and trimethoprim–sulfameth-
oxazole) were detected among S. pneumoniae isolates. b-Lactamase production among
H. influenzae isolates ranged from 6.2% to 33.1% per country, and ampicillin, clarithro-
mycin or trimethoprim–sulfamethoxazole resistance were the most common phenotypes
detected. b-Lactamase production among M. catarrhalis isolates ranged from 94.1% to
100% per country.
Conclusions With the exception of a few localized reports, resistance to moxifloxacin and
other new fluoroquinolones in common respiratory pathogens is a rare occurrence,
despite significant resistance to other compound classes. Surveillance will play a key role
in tracking changes in fluoroquinolone susceptibility in European countries.
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I N T R O D U C T I O N
Antibiotic resistance in Streptococcus pneumoniae,
the primary bacterial cause of community-
acquire/d respiratory tract infections (CA-RTIs),
is a serious cause for concern and places a signi-
ficant burden on community healthcare [1–3]. A
previous study detected significant changes in
S. pneumoniae susceptibility during a two-year
period, and noted the importance of periodic sur-
veillance [4]. This may be especially important for
the newly introduced expanded-spectrum fluoro-
quinolones, such as moxifloxacin, levofloxacin,
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and gatifloxacin [5–7], introduced into the Eur-
opean market for use in the treatment of CA-RTIs.
The effect of growing fluoroquinolone usage on the
susceptibility of S. pneumoniae and other respiratory
pathogens is unclear. We undertook a European
study during the 1997–98 respiratory season to
benchmark the activity of moxifloxacin in relation
to other clinically relevant compounds prior to its
introduction into clinical use [8]. Here we report
the results of a similar study undertaken two years
later, presenting a current perspective on suscept-
ibility, and detecting any changes in antimicrobial
susceptibility that may have occurred, at least for
those countries participating in both studies.
M A T E R I A L S A N D M E T H O D S
During 2000–2001, 1995 isolates of Haemophilus
influenzae, 1870 isolates of S. pneumoniae and 649
isolates of Moraxella catarrhalis were prospectively
collected from 48 hospital laboratory sites in
France (eight sites), Germany (10 sites), Greece
(five sites), Italy (eight sites), Spain (eight sites),
and the UK (nine sites). Where possible, sites
selected were participants in our previous surveil-
lance study [8] and comprised larger community
or university hospitals. All sites were instructed to
forward consecutive isolates, including only one
isolate per patient. Isolates were obtained from
respiratory tract specimens from patients with
community-acquired pneumonia. Upon receipt
at the central laboratory (Focus Technologies,
Herndon, Virginia, USA), isolates were subcul-
tured on blood (S. pneumoniae and M. catarrhalis)
or chocolate (H. influenzae) agar, and their identi-
ties were confirmed by standard laboratory meth-
ods. All H. influenzae and M. catarrhalis isolates
were assessed for b-lactamase production with
nitrocefin (BBL DrySlide Nitrocefin, Becton Dick-
inson, Sparks, MD, USA). Isolates were tested by
the National Committee for Clinical Laboratory
Standards (NCCLS)-defined broth microdilution
method [9] with dried microdilution panels (TREK
Diagnostics, East Grinstead, UK) against penicillin
(S. pneumoniae only), ampicillin (H. influenzae and
M. catarrhalis only), amoxicillin–clavulanate, cefa-
clor, cefdinir, cefuroxime, ceftriaxone, azithromy-
cin, clarithromycin, erythromycin, tetracycline,
gatifloxacin, levofloxacin, moxifloxacin, and tri-
methoprim–sulfamethoxazole. MICs were inter-
preted as susceptible, intermediate or resistant
according to the NCCLS 2002 published break-
points [10]. Ceftriaxone MICs were analyzed using
the non-meningeal breakpoints for S. pneumoniae
that were changed since 2001 [11]. Statistical sig-
nificance was tested using chi-square analysis.
P-values of <0.05 were considered significant.
R E S U L T S
Streptococcus pneumoniae
In total, 99.6% (1863/1870) of the S. pneumoniae
isolates collected were susceptible to moxifloxacin,
gatifloxacin, and levofloxacin. Seven fluoroquino-
Figure 1 MIC distributions of moxi-
floxacin, gatifloxacin, levofloxacin
and ciprofloxacin for 1870 isolates
of S. pneumoniae collected in France,
Germany, Greece, Italy, Spain, and
the UK.
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lone-non-susceptible isolates were collected from
France (one isolate, moxifloxacin MIC 2 mg/L,
gatifloxacin MIC 4 mg/L, levofloxacin MIC
8 mg/L), Germany (one isolate, moxifloxacin
MIC 2 mg/L, gatifloxacin MIC 4 mg/L, levoflox-
acin MIC 8 mg/L), Spain (one isolate, moxifloxacin
MIC 4 mg/L, gatifloxacin MIC 8 mg/L, levoflox-
acin MIC 16 mg/L), and Italy (three isolates,
moxifloxacin MICs 2–4 mg/L, gatifloxacin MICs
4–8 mg/L, levofloxacin MICs 8–16 mg/L). Ele-
vated MICs for ciprofloxacin ( 4 mg/L) were
detected in 35 (1.9%) isolates. MIC distributions
for all S. pneumoniae isolates are shown for all
fluoroquinolones tested (Figure 1). Antimicrobial
susceptibilities to all agents tested are shown in
Table 1. Reduced susceptibility to fluoroquinolones,
although rare, appeared not to be associated with
reduced susceptibility to penicillin, macrolides,
or trimethoprim–sulfamethoxazole. In contrast to
the fluoroquinolones, isolates non-susceptible to
b-lactam and non-b-lactam compounds were
detected in all countries. Specifically, the incidence
of penicillin non-susceptibility was 165/291
(56.7%) in France, 46/506 (9.1%) in Germany,
20/55 (36.4%) in Greece, 45/364 (12.4%) in Italy,
146/268 (54.5%) in Spain, and 26/386 (6.7%) in the
UK, of which resistant isolates represented 26.8%,
1.8%, 18.2%, 4.7%, 26.5% and 2.6% in those coun-
tries, respectively. Azithromycin non-susceptibil-
ity was detected in >50% of isolates in France,
30–40% of isolates in Italy and Spain, and 10–20%
of isolates in Germany, Greece, and the UK. For
all countries, resistance to macrolides, azalides,
tetracyclines and trimethoprim–sulfamethoxazole
was positively associated with penicillin non-
susceptibility (P< 0.01).
Haemophilus influenzae and Moraxella
catarrhalis
The susceptibilities of H. influenzae and M. catar-
rhalis to all antimicrobials tested are shown in
Tables 2 and 3. No H. influenzae isolate tested
had an MIC >0.25 mg/L of any of the fluoroqui-
nolones, with the exception of one isolate from the
UK (ciprofloxacin MIC 0.5 mg/L). MIC90s for all
fluoroquinolones tested were 0.015–0.03 mg/L,
several-fold lower than the susceptibility break-
point, if defined. No M. catarrhalis isolate was
detected with an MIC of any fluoroquinolone
>0.12 mg/L. Fluoroquinolone MIC90s for all coun-
tries were recorded as 0.03–0.06 mg/L.
On the basis of comparisons of median MIC
values for b-lactamase-positive and b-lactamase-
negative strains, b-lactamase production did not
affect fluoroquinolone activity in either species. In
each country, >94% of the M. catarrhalis isolates
tested were b-lactamase positive. In contrast, con-
siderable geographic variation was noted for the
expression of this enzyme class among isolates of
H. influenzae: 33.1% of isolates in France, 10–20% of
isolates in Spain and the UK, and <10% of isolates
in Germany, Greece, and Italy. All compounds
studied demonstrated low MIC90s against M. cat-
arrhalis, which showed little variation between
countries. Among H. influenzae isolates, a varying
prevalence of non-susceptibility was detected for
clarithromycin, trimethoprim–sulfamethoxazole,
and cefaclor.
D I S C U S S I O N
Between this study and our previous 1997–98
study, comprising the same hospitals in Germany,
France, and Italy [8], there has been no detectable
shift in the susceptibility of S. pneumoniae to the
fluoroquinolones, with 99.6% of isolates remaining
susceptible to each fluoroquinolone tested. In the
previous 1997–98 study, five isolates were detected
with levofloxacin MICs 4 mg/L (from a total of
900 S. pneumoniae isolates). Of these, one isolate
was intermediate (MIC 2 mg/L) and one isolate
was resistant (MIC 4 mg/L) to moxifloxacin. The
seven levofloxacin-resistant isolates reported in
this study (of which only two were resistant to
moxifloxacin or gatifloxacin) were derived from
four different countries. As in the previous study,
moxifloxacin was the most potent fluoroquinolone
tested against S. pneumoniae, with an MIC90 in this
study of 0.12 mg/L, compared with 1 mg/L for
levofloxacin and 0.25 mg/L for gatifloxacin.
MIC90s remained constant in each country stu-
died, demonstrating the uniform susceptibility
of pneumococci to this compound class. When
considering ciprofloxacin MIC distributions as a
potential marker for reduced fluoroquinolone sus-
ceptibility, only 35 S. pneumoniae isolates were
tested with an MIC 4 mg/L; 19 of these isolates
had an MIC of 4 mg/L. Considering the MIC
distributions presented (Figure 1), which are
essentially identical to those previously published
[8], it seems that S. pneumoniae isolates from all
regions studied comprise a stable fluoroquino-
lone-susceptible population. The increase in the
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Table 1 Antimicrobial susceptibility of S. pneumoniae to all antimicrobials according to penicillin status. MIC90 values are shown in mg/L
Francea Germanyb Greecec Italyd Spaine UKf
Antimicrobial MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R
Penicillin
All 2 43.3 29.9 26.8 0.06 90.9 7.3 1.8 2 63.6 18.2 18.2 0.12 87.6 7.7 4.7 2 45.5 26.5 28.0 0.03 93.3 4.1 2.6
Pen S 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0
Pen I 1 0 100 0 1 0 100 0 1 0 100 0 1 0 100 0 1 0 100 0 1 0 100 0
Pen R 4 0 0 100 2 0 0 100 4 0 0 100 2 0 0 100 4 0 0 100 2 0 0 100
Amoxicillin–clavulanate
All 2 96.6 2.4 1.0 0.03 100 0 0 1 100 0 0 0.06 100 0 0 4 89.2 6.0 4.9 0.03 99.0 1.0 0
Pen S 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0
Pen I 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0
Pen R 4 87.2 9.0 3.8 2 100 0 0 2 100 0 0 2 100 0 0 8 61.3 21.3 17.3 4 60.0 40.0 0
Ceftriaxone
All 1 97.3 2.7 0 0.06 100 0 0 1 100 0 0 0.06 99.7 0.3 0 1 96.3 3.7 0 0.03 100 0 0
Pen S 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0 0.03 100 0 0
Pen I 1 98.9 1.1 0 0.5 100 0 0 1 100 0 0 0.5 100 0 0 1 100 0 0 1 100 0 0
Pen R 1 91.0 9.0 0 1 100 0 0 1 100 0 0 1 94.1 5.9 0 2 86.7 13.3 0 1 100 0 0
Cefaclor
All >32 49.8 3.1 47.1 1 91.9 3.2 4.9 >32 63.6 3.6 32.7 2 88.7 4.4 6.9 >32 48.9 2.6 48.5 1 94.0 1.3 4.7
Pen S 1 99.2 0.8 0 1 98.5 1.5 0 1 100 0 0 1 96.6 3.4 0.0 1 98.4 1.6 0.0 1 99.4 0.6 0
Pen I >32 23.0 9.2 67.8 32 32.4 24.3 43.2 >32 0 20.0 80.0 >32 53.6 17.9 28.6 >32 15.5 7.0 77.5 >32 31.3 18.8 50.0
Pen R >32 0 0.0 100 >32 0 0 100 >32 0 0 100 >32 0 0 100 >32 0 0 100 >32 0 0 100
Cefdinir
All >2 54.6 1.7 43.6 0.12 95.8 0.6 3.6 >2 67.3 0 32.7 0.25 93.7 0.3 6.0 >2 53.4 4.9 41.8 0.12 95.3 0.3 4.4
Pen S 0.06 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0.0 0.0 0.12 100 0 0 0.06 100 0 0
Pen I >2 37.9 5.7 56.3 >2 67.6 8.1 24.3 >2 20.0 0 80.0 >2 78.6 3.6 17.9 >2 29.6 18.3 52.1 >2 50.0 6.3 43.8
Pen R >2 0 0 100 >2 0 0 100 >2 0 0 100 >2 0 0 100 >2 0 0 100 >2 0 0 100
Cefuroxime
All 8 54.3 4.8 40.9 0.25 96.0 0.6 3.4 4 67.3 7.3 25.5 0.5 94.0 0.3 5.8 8 54.5 6.3 39.2 0.12 95.3 0.5 4.1
Pen S 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0
Pen I 4 36.8 14.9 48.3 4 70.3 8.1 21.6 4 20.0 40.0 40.0 4 82.1 3.6 14.3 4 33.8 23.9 42.3 8 50.0 12.5 37.5
Pen R 8 0 1.3 98.7 8 0 0 100 8 0 0 100 8 0 0 100 8 0 0 100 8 0 0 100
Erythromycin
All >4 41.9 0 58.1 >4 83.6 0.2 16.2 >4 81.8 1.8 16.4 >4 69.5 0.5 29.9 >4 62.7 0.4 36.9 4 87.3 0.5 12.2
Pen S >4 77.0 0 23.0 4 88.0 0.2 11.7 0.03 94.3 2.9 2.9 >4 74.0 0.3 25.7 >4 86.1 0 13.9 0.06 90.0 0.3 9.7
Pen I >4 20.7 0 79.3 >4 37.8 0 62.2 >4 80.0 0 20.0 >4 32.1 0 67.9 >4 39.4 0 60.6 >4 68.8 6.3 25.0
Pen R >4 9.0 0 91.0 >4 44.4 0 55.6 >4 40.0 0 60.0 >4 47.1 5.9 47.1 >4 46.7 1.3 52.0 >4 20.0 0 80.0
Azithromycin
All >16 42.3 0 57.7 16 83.8 0.4 15.8 4 85.5 1.8 12.7 >16 70.1 0 29.9 >16 63.1 0 36.9 4 88.1 0 11.9
Pen S >16 77.0 0 23.0 4 88.3 0.4 11.3 0.06 100 0 0 >16 74.3 0 25.7 >16 86.1 0 13.9 0.06 90.6 0 9.4
Pen I >16 20.7 0 79.3 >16 37.8 0 62.2 >16 80.0 0 20.0 >16 32.1 0 67.9 >16 39.4 0 60.6 > 16 75.0 0 25.0
Pen R >16 10.3 0 89.7 >16 44.4 0 55.6 >16 40.0 10.0 50.0 >16 52.9 0 47.1 >16 48.0 0 52.0 > 16 20.0 0 80.0
Clarithromycin
All >16 41.9 0.3 57.7 16 83.8 0 16.2 >16 81.8 1.8 16.4 >16 70.1 0.8 29.1 >16 63.1 0 36.9 4 87.6 0.3 12.2
Pen S >16 77.0 0 23.0 4 88.3 0 11.7 0.03 94.3 2.9 2.9 >16 74.3 0.9 24.8 >16 86.1 0 13.9 0.06 90.0 0 10.0
Pen I >16 20.7 0 79.3 >16 37.8 0 62.2 >16 80.0 0 20.0 >16 32.1 0 67.9 >16 39.4 0 60.6 >16 75.0 6.3 18.8
Pen R >16 9.0 1.3 89.7 >16 44.4 0 55.6 >16 40.0 0 60.0 >16 52.9 0 47.1 >16 48.0 0 52.0 >16 20.0 0 80.0

2003
C
o
p
y
rig
h
t
b
y
th
e
E
u
ro
p
ean
S
o
ciety
o
f
C
lin
ical
M
icro
b
io
lo
g
y
an
d
In
fectio
u
s
D
iseases,
C
M
I,
9,
590–599
Jo
n
es
et
a
l
In
v
itro
su
scep
tib
ility
o
f
S
.
pn
eu
m
on
iae,
H
.
in
flu
en
zae
an
d
M
.
catarrhalis
593
Table 1 continued
Francea Germanyb Greecec Italyd Spaine UKf
Antimicrobial MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R
Tetracycline
All >16 55.7 2.1 42.3 >16 85.8 0.4 13.8 >16 83.6 0 16.4 >16 76.4 1.9 21.7 >16 63.4 1.5 35.1 0.5 95.9 0.3 3.9
Pen S >16 80.2 2.4 17.5 1 91.3 0.2 8.5 0.5 97.1 0 2.9 >16 80.3 1.9 17.9 16 86.9 0.8 12.3 0.5 98.3 0.3 1.4
Pen I >16 44.8 2.3 52.9 >16 32.4 2.7 64.9 16 80.0 0 20.0 >16 35.7 3.6 60.7 >16 39.4 1.4 59.2 >16 62.5 0 37.5
Pen R >16 28.2 1.3 70.5 >16 22.2 0 77.8 >16 40.0 0 60.0 >16 70.6 0 29.4 >16 48.0 2.7 49.3 >16 60.0 0 40.0
Ciprofloxacin
All 2 – g – – 2 – – – 2 – – – 2 – – – 2 – – – 2 – – –
Pen S 2 – – – 2 – – – 2 – – – 2 – – – 2 – – – 2 – – –
Pen I 2 – – – 2 – – – 1 – – – 2 – – – 2 – – – 2 – – –
Pen R 1 – – – 2 – – – 1 – – – 1 – – – 1 – – – 2 – – –
Gatifloxacin
All 0.25 99.7 0 0.3 0.25 99.8 0 0.2 0.25 100 0 0 0.25 98.9 0 1.1 0.25 99.6 0 0.4 0.25 100 0 0
Pen S 0.25 99.2 0 0.8 0.25 99.8 0 0.2 0.25 100 0 0 0.25 99.1 0 0.9 0.25 100 0 0 0.25 100 0 0
Pen I 0.25 100 0 0 0.25 100 0 0 0.25 100 0 0 0.25 96.4 0 3.6 0.25 98.6 0 1.4 0.25 100 0 0
Pen R 0.25 100 0 0 0.25 100 0 0 0.25 100 0 0 0.25 100 0 0 0.25 100 0 0 0.25 100 0 0
Levofloxacin
All 1 99.7 0 0.3 1 99.8 0 0.2 1 100 0 0 1 98.9 0 1.1 1 99.6 0 0.4 1 100 0 0
Pen S 1 99.2 0 0.8 1 99.8 0 0.2 1 100 0 0 1 99.1 0 0.9 1 100 0 0 1 100 0 0
Pen I 1 100 0 0 1 100 0 0 1 100 0 0 1 96.4 0 3.6 1 98.6 0 1.4 1 100 0 0
Pen R 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0 1 100 0 0
Moxifloxacin
All 0.12 99.7 0.3 0 0.12 100 0 0 0.12 100 0 0 0.12 98.9 0.8 0.3 0.12 99.6 0 0.4 0.12 100 0 0
Pen S 0.12 99.2 0.8 0 0.12 100 0 0 0.12 100 0 0 0.12 99.1 0.9 0 0.12 100 0 0 0.12 100 0 0
Pen I 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 96.4 0 3.6 0.12 98.6 0 1.4 0.12 100 0 0
Pen R 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0 0.12 100 0 0
Trimethoprim–
sulfamethoxazole
All 8 58.8 11.3 29.9 2 84.0 8.1 7.9 8 60.0 12.7 27.3 2 74.2 15.9 9.9 8 42.5 11.9 45.5 0.5 90.4 4.1 5.4
Pen S 0.5 92.1 5.6 2.4 1 89.1 7.0 3.9 1 85.7 11.4 2.9 2 80.6 15.0 4.4 4 69.7 11.5 18.9 0.25 95.6 2.8 1.7
Pen I 8 44.8 17.2 37.9 8 40.5 21.6 37.8 8 20.0 10.0 70.0 4 42.9 35.7 21.4 8 33.8 11.3 54.9 4 25.0 31.3 43.8
Pen R 8 20.5 14.1 65.4 8 0 11.1 88.9 8 10.0 20.0 70.0 8 5.9 0 94.1 8 6.7 13.3 80.0 8 10.0 10.0 80.0
a291 isolates collected; 126 Pen S, 87 Pen I, 78 Pen R.
b506 isolates collected; 460 Pen S, 37 Pen I, 9 Pen R.
c55 isolates collected; 35 Pen S, 10 Pen I, 10 Pen R.
d364 isolates collected; 319 Pen S, 28 Pen I, 17 Pen R.
e268 isolates collected; 122 Pen S, 71 Pen I, 75 Pen R.
f386 isolates collected; 360 Pen S, 16 Pen I, 10 Pen R.
gNCCLS published breakpoints unavailable for categorical interpretation as susceptible (S), intermediate (I), or resistant (R) [10,11].
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Table 2 Antimicrobial susceptibility of H. influenzae to all antimicrobials according to b-lactamase status. MIC90 values are shown in mg/L
Francea Germanyb Greecec Italyd Spaine UKf
Antimicrobial MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R
Ampicillin
All >16 66.5 1.5 32.0 0.5 91.9 0 8.1 1 93.8 0 6.2 1 92.0 0 8.0 >16 80.3 0.3 19.4 >16 86.1 0.4 13.4
Positive >16 0 3.3 96.7 >16 0 0 100 >16 0 0 100 >16 0 0 100 >16 0 0 100 >16 1.6 1.6 96.8
Negative 0.5 99.5 0.5 0 0.25 100 0 0 0.5 100 0 0 0.5 100 0 0 0.5 99.3 0.4 0.4 0.5 99.7 0.3 0
Amoxicillin–clavulanate
All 1 99.6 – g 0.4 0.5 100 – 0 1 100 – 0 1 100 – 0 1 100 – 0 1 100 – 0
Positive 2 98.9 – 1.1 1 100 – 0 2 100 – 0 2 100 – 0 2 100 – 0 2 100 – 0
Negative 1 100 – 0 0.5 100 – 0 1 100 – 0 0.5 100 – 0 1 100 – 0 1 100 – 0
Ceftriaxone
All 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Positive 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Negative 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Cefaclor
All 8 92.0 6.2 1.8 4 97.5 1.6 1.0 8 96.9 1.5 1.5 4 97.2 2.0 0.9 16 89.7 5.3 5.0 4 96.2 2.0 1.8
Positive 16 76.9 17.6 5.5 16 83.3 9.5 7.1 32 50.0 25.0 25.0 32 75.0 14.3 10.7 >32 61.5 13.8 24.6 32 79.0 8.1 12.9
Negative 4 99.5 0.5 0 4 98.7 0.8 0.4 4 100 0 0 4 99.1 0.9 0.0 4 96.4 3.3 0.4 4 99.0 1.0 0.0
Cefdinir
All 0.5 100 – – 0.5 99.8 – – 0.5 100 – – 0.5 100 – – 0.5 99.4 – – 0.5 100 – –
Positive 0.5 100 – – 1 100 – – 0.5 100 – – 0.5 100 – – 0.5 100 – – 0.5 100 – –
Negative 0.5 100 – – 0.5 99.8 – – 0.5 100 – – 0.5 100 – – 0.5 99.3 – – 0.5 100 – –
Cefuroxime
All 2 100 0 0 1 99.8 0.2 0 2 100 0 0 1 100 0 0 2 99.4 0.6 0 2 99.8 0.2 0
Positive 2 100 0 0 2 100 0 0 2 100 0 0 2 100 0 0 2 100 0 0 1 100 0 0
Negative 2 100 0 0 1 99.8 0.2 0 2 100 0 0 1 100 0 0 2 99.3 0.7 0 2 99.7 0.3 0
Erythromycin
All >4 – – – >4 – – – >4 – – – >4 – – – >4 – – – >4 – – –
Positive >4 – – – >4 – – – >4 – – – >4 – – – >4 – – – >4 – – –
Negative >4 – – – >4 – – – >4 – – – >4 – – – >4 – – – >4 – – –
Azithromycin
All 2 99.6 – – 2 100 – – 2 100 – – 2 100 – – 2 99.7 – – 2 100 – –
Positive 2 100 – – 1 100 – – 2 100 – – 1 100 – – 2 100 – – 1 100 – –
Negative 2 99.5 – – 2 100 – – 2 100 – – 2 100 – – 2 99.6 – – 2 100 – –
Clarithromycin
All 16 79.3 20.4 0.4 16 77.9 21.7 0.4 16 70.8 27.7 1.5 16 76.4 23.6 0 16 74.4 24.1 1.5 16 78.1 21.9 0
Positive 16 69.2 30.8 0 16 81.0 19.0 0 16 50.0 50.0 0 16 82.1 17.9 0 16 69.2 29.2 1.5 16 82.3 17.7 0
Negative 16 84.2 15.2 0.5 16 77.6 21.9 0.4 16 72.1 26.2 1.6 16 75.9 24.1 0 16 75.6 22.9 1.5 16 77.4 22.6 0
Tetracycline
All 1 95.3 0 4.7 1 99.4 0.4 0.2 1 98.5 0 1.5 1 100 0 0 1 96.2 0.6 3.2 1 97.8 0.2 2.0
Positive 8 89.0 0 11.0 1 95.2 2.4 2.4 16 75.0 0 25.0 0.5 100 0 0 16 81.5 3.1 15.4 8 83.9 1.6 14.5
Negative 0.5 98.4 0 1.6 1 99.8 0.2 0 1 100 0 0 1 100 0 0 1 99.6 0 0.4 1 100 0 0
Ciprofloxacin
All 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Positive 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Negative 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
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Table 2 continued
Francea Germanyb Greecec Italyd Spaine UKf
Antimicrobial MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R MIC90 % S % I % R
Gatifloxacin
All 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Positive 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Negative 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Levofloxacin
All 0.015 100 – – 0.015 100 – – 0.03 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Positive 0.015 100 – – 0.015 100 – – 0.03 100 – – 0.015 100 – – 0.015 100 – – 0.03 100 – –
Negative 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – – 0.015 100 – –
Moxifloxacin
All 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – –
Positive 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – –
Negative 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – – 0.03 100 – –
Trimethoprim–sulfamethoxazole
All 8 82.2 3.6 14.2 4 80.6 5.6 13.8 4 84.6 1.5 13.8 4 82.7 4.8 12.5 8 62.6 4.1 33.2 4 84.6 3.8 11.6
Positive 0.5 90.1 0 9.9 8 85.7 0 14.3 4 75.0 0 25.0 8 71.4 7.1 21.4 8 56.9 0 43.1 8 82.3 3.2 14.5
Negative 8 78.3 5.4 16.3 4 80.2 6.1 13.7 4 85.2 1.6 13.1 4 83.6 4.6 11.7 8 64.0 5.1 30.9 4 84.9 3.9 11.2
a275 isolates collected; 91 (33.1%) b-lactamase positive.
b516 isolates collected; 42 (8.1%) b-lactamase positive.
c65 isolates collected; four (6.2%) b-lactamase positive.
d352 isolates collected; 28 (8.0%) b-lactamase positive.
e340 isolates collected; 65 (19.1%) b-lactamase positive.
f447 isolates collected; 62 (13.9%) b-lactamase positive.
gNCCLS published breakpoints unavailable for categorical interpretation as susceptible (S), intermediate (I), or resistant (R) [10,11].
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number of fluoroquinolone-resistant isolates be-
tween the two studies (5–7 levofloxacin-resistant
isolates; 1–2 moxifloxacin-resistant isolates) con-
stitutes a very small change, especially considering
the high prevalence of resistance to other com-
pounds detected. So far, very little fluoro-
quinolone resistance has been detected, despite
considerable variation in the use of this class of
antibiotics in the countries studied. In France,
where moxifloxacin was not available for use at
the time of this study, resistance to moxifloxacin
was detected, while in Germany, where moxiflox-
acin has been widely used since its introduction in
1999, no resistance was detectable. Clearly, the use
of other fluoroquinolone compounds such as levo-
floxacin, widely available since 1998, can have an
impact on moxifloxacin resistance (and vice versa),
given the tendency for cross-resistance to develop
among this compound class. Future studies should
take antibiotic usage into consideration, and relate
this to detected changes in susceptibility. Studies
in Canada, Hong Kong and other parts of the
world have recorded increases in the prevalence
of fluoroquinolone resistance [12–14]. In Hong
Kong, increases in resistance have resulted from
clonal spread [14], probably a dominant factor that
should be considered elsewhere in the world, in
which improved infection control can play an
important role. However, it has also been reported
that distributions of ciprofloxacin MICs for S.
pneumoniae in the USA have remained constant
during the past 10 years [15], despite the predo-
minant use of fluoroquinolones for CA-RTIs.
Therefore, factors affecting the emergence of resis-
tance vary geographically. Recent studies have
shown that more active fluoroquinolones, such
as moxifloxacin and gatifloxacin, are potentially
less likely to select for resistance mutations, if
mutation prevention concentrations are consid-
ered in relation to achievable serum levels [16],
although this requires further study.
Among M. catarrhalis and H. influenzae, two
other species commonly implicated in RTIs, no
isolates were detected that were resistant to any
of the fluoroquinolones tested (using the FDA sus-
ceptible breakpoint of 1 mg/L for moxifloxacin
to interpret M. catarrhalis MICs), and there was no
change in MIC distributions compared to the pre-
vious 1997–98 data. However, vigilance is required,
since one report from the USA demonstrated the
appearance of H. influenzae with elevated MICs to
levofloxacin and other fluoroquinolones [17]. Such
Table 3 Antimicrobial susceptibility of M. catarrhalis to all antimicrobialsa
MIC90 (mg/L)
Antimicrobial Franceb Germanyc Greeced Italye Spainf UKg
Ampicillin 4 4 4 4 8 4
Amoxicillin–clavulanate 0.25 0.25 0.25 0.25 0.25 0.25
Ceftriaxone 0.5 0.5 0.5 0.5 0.5 0.5
Cefaclor 1 1 1 1 1 1
Cefdinir 0.25 0.25 0.25 0.25 0.25 0.25
Cefuroxime 2 2 2 2 2 2
Erythromycin 0.25 0.25 0.25 0.25 0.25 0.25
Azithromycin 0.06 0.06 0.06 0.06 0.06 0.06
Clarithromycin 0.25 0.12 0.12 0.12 0.12 0.12
Tetracycline 0.5 0.5  0.25 0.5 0.5 0.5
Ciprofloxacin 0.03 0.03 0.03 0.06 0.03 0.03
Gatifloxacin 0.03 0.03 0.03 0.03 0.03 0.03
Levofloxacin 0.06 0.06 0.06 0.06 0.06 0.06
Moxifloxacin 0.06 0.06 0.06 0.06 0.06 0.06
Trimethoprim–sulfamethoxazole 0.5 0.25 0.25 0.25 1 0.25
aNCCLS published breakpoints unavailable for categorical interpretation as susceptible (S), intermediate (I), or resistant (R)
[10,11].
b100 isolates collected; 98 (98.0%) b-lactamase positive.
c181 isolates collected; 174 (96.1%) b-lactamase positive.
d30 isolates collected; 30 (100%) b-lactamase positive.
e102 isolates collected; 97 (95.1%) b-lactamase positive.
f101 isolates collected; 96 (95.0%) b-lactamase positive.
g135 isolates collected; 127 (94.1%) b-lactamase positive.
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phenotypes are clearly very rare, as this study and
other large surveillance studies in the USA have
not detected them [18,19].
Despite the introduction of expanded-spectrum
fluoroquinolones into clinical practice, b-lactams
and macrolides remain the recommended empiri-
cal therapies for CA-RTI where a non-viral patho-
gen is suspected. For this reason, tracking changes
in susceptibility to b-lactams and other agents
remains important. For France, Germany, and
Italy, it would appear that the prevalence of peni-
cillin non-susceptibility has increased during the
last 2 years, since the 1997–98 study recorded rates
of 45.0%, 5.3%, and 7.9%, respectively, for those
countries, compared with the 56.7%, 9.1% and
12.4% recorded here [8]. The proportion of resis-
tant isolates, more likely to have an impact on
clinical outcome, also increased for France, Ger-
many, and Italy, from 19.4%, 0.7% and 2.0% in the
1997–98 study to 26.8%, 1.8% and 4.7% in this
study. Data from the 1998 Alexander Project
recorded the incidence of penicillin non-suscept-
ibility in those countries as 53.3%, 7.1%, and 9.0%
[20], still lower than the rates reported here. Addi-
tionally, for Greece, the Alexander Project
reported a 31.6% incidence of penicillin non-sus-
ceptibility, compared to 36.4% in this study [20].
For Spain, a 1996–97 study reported 39.4% of
isolates to be resistant, compared to the 27.9%
resistance recorded here [21]. Other regional stu-
dies (1999–2000) have reported non-susceptibility
rates of up to 65.6% among isolates collected in
Spain [22]. In this study, the same or higher levels
of macrolide resistance were recorded in the var-
ious countries compared to previous studies
[8,19,20,23]. It is of note that we did not detect
any further increases in the incidence of macrolide
resistance in Italy, as anticipated by the Alexander
Project [20].
For M. catarrhalis and H. influenzae, susceptibil-
ity profiles remained essentially unchanged from
the previous 1997–98 studies [8,19], with the only
significant resistance detected being that conferred
by the expression of b-lactamase, and, for H. influ-
enzae, resistance to trimethoprim–sulfamethoxa-
zole, tetracycline, and clarithromycin. For M.
catarrhalis, >94% of isolates in all countries pro-
duced b-lactamase. This represents an increase in
prevalence compared to our previous studies, in
which 80–90% of isolates were b-lactamase posi-
tive. In contrast, b-lactamase production in H.
influenzae remains variable. Noticeable increases
in the prevalence of b-lactamase expression in this
species have occurred in France (33.1%, compared
to 22–27% in previous studies) [19,20], while a
decrease was recorded in Spain (19.0%, compared
to 32% recorded previously) [19].
In summary, 99.6% of S. pneumoniae isolates and
100% of M. catarrhalis and H. influenzae isolates
remain susceptible to moxifloxacin, levofloxacin,
and gatifloxacin, with moxifloxacin showing the
highest in vitro activity. Continued monitoring,
especially at local and national levels, will be
required to detect any further changes in pathogen
susceptibility, should they occur.
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